

GUNKUL ENGINEERING
THAILAND / UTILITIES - RENEWABLES

GUNKUL TB

BUY

UNCHANGED

On the hemp growth radar

- เราเชื่อว่าโครงสร้างกำไรสุทธิของ GUNKUL จะอยู่ในช่วงของการเติบโตในระดับสูงตั้งแต่ปี 2022 เป็นต้นไป
- ในฐานะที่เป็นหนึ่งในผู้ที่เข้าสู่ธุรกิจเป็นรายแรก GUNKUL ได้ประสบความสำเร็จในการปลูกและสกัด CBD เพื่อการค้า
- คงแนะนำซื้อแต่ปรับลดราคาเป้าหมายเป็น 6.6 บาท (SoTP)

TARGET PRICE	THB6.60
CLOSE	THB5.50
UP/DOWNSIDE	+20.0%
PRIOR TP	THB8.10
CHANGE IN TP	-18.5%
TP vs CONSENSUS	-0.5%

KEY STOCK DATA

YE Dec (THB m)	2021	2022E	2023E	2024E
Revenue	9,318	10,482	12,555	12,882
Net profit	2,229	2,273	3,622	3,938
EPS (THB)	0.25	0.26	0.41	0.44
vs Consensus (%)	-	(28.2)	2.5	(18.5)
EBITDA	3,995	4,225	5,817	6,135
Core net profit	1,909	2,273	3,622	3,938
Core EPS (THB)	0.21	0.26	0.41	0.44
Chg. In EPS est. (%)	0.0	(41.1)	(10.9)	(33.3)
EPS growth (%)	49.5	19.1	59.3	8.7
Core P/E (x)	25.6	21.5	13.5	12.4
Dividend yield (%)	3.3	4.4	4.4	4.4
EV/EBITDA (x)	18.0	16.8	11.9	10.9
Price/book (x)	3.7	3.5	3.2	2.9
Net debt/Equity (%)	173.3	154.6	127.8	100.1
ROE (%)	15.0	16.9	24.9	24.3

การเปลี่ยนแปลงครั้งที่สองเพื่อเข้าสู่ธุรกิจที่เกี่ยวข้องกับกัญชง

นับตั้งแต่ GUNKUL เปลี่ยนจากบริษัทออกแบบจัดหาพร้อมติดตั้งและบริหารการค้าที่มีอัตรากำไรต่ำและมีความผันผวนสูงเป็นองค์กรที่ขับเคลื่อนโดยธุรกิจโรงไฟฟ้าที่มีความยั่งยืนสูงกว่าพร้อมกำไรที่โตอย่างมีนัยสำคัญจากธุรกิจพลังงานหมุนเวียน เราเชื่อว่าโครงสร้างกำไรสุทธิของ GUNKUL จะอยู่ในช่วงเติบโตสูงนับตั้งแต่ปี 2022 เป็นต้นไป เราเห็นว่าปัจจัยขับเคลื่อนสำคัญจะอยู่ที่กลุ่มธุรกิจกัญชงและกัญชงอัดรวมด้วยธุรกิจการทำไรต์น้า ธุรกิจสกัดสารเคมี กลางน้ำ และธุรกิจอาหารและเครื่องดื่ม รวมถึงผลิตภัณฑ์ยาที่ใช้สารสกัด CBD จากกัญชงและกัญชาปลายน้ำ

กัญชงกำลังเข้าสู่ตลาด


นับตั้งแต่ช่วง 2H22 เป็นต้นไปเราคาดว่าสัดส่วนของกำไรสุทธิของ GUNKUL จากธุรกิจกัญชงจะโตเป็น 27% ในปี 2022, 45% ในปี 2023, และ 59% ในปี 2024 จากการขายดอกกัญชงต้นน้ำและ CBD Isolate รวมถึงสารสกัดกลางน้ำต่าง ๆ เมื่อพิจารณาจากความสำเร็จในการทำไรต์กัญชงกึ่งในร่มแห่งแรกพร้อมปริมาณการผลิตที่ดอกกัญชงจำนวน 0.5t ในเดือน พ.ค. 22 ธุรกิจกัญชงน่าจะช่วยเพิ่มกำไรสุทธิต่อปีของ GUNKUL จากค่าเฉลี่ยที่ 2 พัน ลบ. ในปี 2017-21 เป็น 3.5 พัน ลบ. ตั้งแต่ปี 2023 เป็นต้นไป GUNKUL ได้สร้างรากฐานในอุตสาหกรรมกัญชงและกำลังขยายเข้าสู่ตลาดใหม่ในต่างประเทศในปัจจุบัน ในขณะที่บริษัทฯ จับความต้องการผลิตภัณฑ์ CBD และกัญชงในตลาดในประเทศ

ความเสี่ยงในด้านอุปสงค์ลดลงจากการยึดตลาดในประเทศและการส่งออก

ในฐานะที่เป็นหนึ่งในบริษัทที่เข้าสู่ธุรกิจกัญชงเป็นรายแรก ๆ ในประเทศไทย GUNKUL ได้ประสบความสำเร็จในการปลูกและสกัด CBD เพื่อการค้าทั้งในตลาดในประเทศและส่งออก เพื่อลดความเสี่ยงในด้านอุปสงค์ในระยะเริ่มต้น GUNKUL ได้จับอุปสงค์ระยะยาวสำหรับสารสกัด CBD และดอกกัญชงผ่านสัญญาระยะยาวเพื่อจัดตั้งสารละลาย CBD, สารสกัด CBD, และไปกัญชงให้แก่ CPF และ Black Canyon ซึ่งเป็นหนึ่งในร้านกาแฟและอาหารชั้นนำของประเทศไทย

ยังเป็นหนึ่งในหุ้นที่ดีที่สุดในประเทศไทยในประเด็นตลาดกัญชงที่กำลังเติบโตสูง

เราคงแนะนำซื้อหลังปรับลดราคาเป้าหมายจาก 8.2 เป็น 6.6 บาท (SoTP) เพื่อสะท้อนการปรับลดประมาณการกำไรต่อหุ้นปี 2022-24 ลง 63%/3.9%/16% เพื่อรวมสมมติฐานระดับการผลิตดอกกัญชงและผลิตภัณฑ์ที่เกี่ยวข้องที่ลดลงจากความล่าช้าในการออกกฎหมายการใช้และบริโภคกัญชงที่นานเกินคาด เราคิดว่ากำไรเติบโตของกำไรสุทธิของ GUNKUL จะได้แรงขับเคลื่อนและเปลี่ยนแปลงจากธุรกิจกัญชงในปี 2022-24 โดยเราคาดว่ากำไรสุทธิจะโตจาก 0.6 พัน ลบ. ในปี 2022 เป็น 2.3 พัน ลบ. ในปี 2024



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	11.8	(6.0)	29.7
Relative to country (%)	11.1	(1.6)	32.3
Mkt cap (USD m)	1,395		
3m avg. daily turnover (USD m)	12.3		
Free float (%)	44		
Major shareholder	GUNKUL Group Plc (50%)		
12m high/low (THB)	7.20/4.08		
Issued shares (m)	7,418.62		

Sources: Bloomberg consensus; FSSIA estimates



Suwat Sinsadok, CFA, FRM, ERP

suwat.sin@fssia.com
+66 2611 3558

Siriluck Pinthusoonthorn

siriluck.pin@fssia.com
+66 2611 3562

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากบทวิเคราะห์ของ FSSIA ฉบับวันที่ 16 มิถุนายน 2022

Investment thesis

GUNKUL is well positioned to capture Thailand's renewable energy (solar and wind power) growth, both as an operator and through engineering, procurement and construction (EPC), in our view. Its core power equipment trading business could further benefit from the LED boom, while its strong ties with the Myanmar government (20-year relationship) could enhance its earnings growth from power plants.

We expect contributions from its cannabis business to rise to 27% of its total net profit in 2022. GUNKUL is poised to register strong earnings growth, in our view, driven by potential net profit growth from its renewable power projects in Vietnam and higher net profits from its EPC backlog of THB11b from large-scale bidding for power substations and transmission lines. GUNKUL is likely to also see net profit growth from its new cannabis venture in 2022 onward.


Company profile

GUNKUL is one of the largest renewable plays in Thailand with capacities for solar, wind, and gas engine power plants in Thailand and Myanmar.

www.gunkul.com

Principal activities (revenue, 2021)


- Manufacturing and selling of equipment for electrical systems - 16.1 %
- Generating and selling electricity - 52.5 %
- Construction service - 32.2 %



Source: Gunkul Engineering

Major shareholders

- GUNKUL Group Plc - 49.8 %
- Others - 50.2 %



Source: Gunkul Engineering

Catalysts

Higher utilisation rates of power plants and rising demand for electricity in Thailand and Japan are key potential growth drivers.

Risks to our call

The downside risks to our SoTP-based TP on GUNKUL include 1) lower-than-expected demand for electricity in Thailand, 2) declining EPC backlogs, and 3) lower-than-expected utilisation rates for solar and wind farms.

Event calendar

Date	Event
Aug 2022	2Q22 results announcement

Key assumptions

	2022E	2023E	2024E
EPC revenue (THB m)	1,000	1,200	1,000
Trading revenue (THB m)	1,483	1,483	1,483
Cannabis flower production (kg)	11,604	29,011	58,022
Cannabis spectrum production (kg)	2,089	5,222	10,444
Cannabis CBD production (kg)	1,083	2,708	5,415
Cannabis net profit (THB m)	619	1,612	2,321

Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in the gas price, we estimate 2022 earnings would rise by 1.1%, and vice versa, all else being equal.
- For every 1% increase in interest rate, we estimate 2022 earnings would fall by 1.3%, and vice versa, all else being equal.
- For every 1% increase in power utilisation rate, we estimate 2022 earnings would rise by 1.3%, and vice versa, all else being equal.


Source: FSSIA estimates

On the hemp growth radar

Since 2017, GUNKUL has successfully transformed itself from a low-margin, highly volatile engineering, procurement, and contractor (EPC) and trading company to a more sustainable, power-driven organisation with significant earnings growth from renewable energy, mainly from its 180MW wind farm projects.


In 4Q20, GUNKUL restructured its asset portfolio, monetising its solar farm assets in Japan via divestments to raise capital to fund its next new S-curve growth project, which will focus on the hemp and cannabis business value chain that covers upstream farming, mid-stream extraction, and downstream food & beverages (F&B) and pharmaceutical products using the cannabidiol (CBD) extracted from hemp and cannabis.

Exhibit 1: Quarterly net profit



Source: GUNKUL


Exhibit 2: Quarterly core net profit



Source: GUNKUL


Hemp growth to kick start in 2H22. Starting in 2H22 onward, we project that GUNKUL will begin to see rising net profits generated from its hemp venture, given the success of its first semi-indoor hemp farm with a total production volume of 0.5 tonnes of hemp flowers in May-22.

Exhibit 3: Net profit breakdown by segment



Sources: GUNKUL; FSSIA estimates


Exhibit 4: Core net profit and core net profit growth



Sources: GUNKUL; FSSIA estimates

The advent of the earnings from the hemp venture is likely to lift GUNKUL's earnings band from an average of THB2b annually in 2017-21 to THB3.5b in 2023 onwards, driven mainly by the earnings generated from the sale of upstream hemp and cannabis flowers for the export market, according to management. In 2022, we expect the earnings from hemp to remain small as GUNKUL is expanding into new markets overseas and securing demand for CBD and hemp products in the domestic market.

Exhibit 5: Net profit breakdown by segment (%)



Sources: GUNKUL; FSSIA estimates



We project the net profit proportion from cannabis and hemp to grow from zero in 2021 to 27% in 2022, 45% in 2023, and 59% in 2024, derived from the sale of upstream hemp & cannabis (HC) flowers for both the domestic and export markets and mid-stream CBD isolate and full spectrum extracts.

According to management, GUNKUL is now seeking new markets for its HC flowers, which are projected to rise from 38.7k in 2022 to 193.4k in 2024, based on a projected farming area of 100 rai for the 100 semi-indoor greenhouses at 20 rai in 2022, rising to 50 rai in 2023 and 100 rai in 2024.

Our assumptions include the sale of HC flowers (35% of production yield), full spectrum (30%), CBD extract (30%), and HC leaves, trees, and roots (5%). We project that GUNKUL will generate earnings from its hemp and cannabis venture of THB0.6b in 2022, THB1.6b in 2023, and THB2.3b in 2024, driven by higher sales volumes, mainly for the export of hemp flowers, and rising revenues from the CBD and hemp-related products.

Exhibit 6: Forecasts of hemp farming area vs production of hemp and cannabis flowers, full spectrum, and CBD extract

Exhibit 7: Net profit projections vs production of hemp and cannabis flowers, full spectrum, and CBD extract



Sources: GUNKUL; FSSIA estimates

Sources: GUNKUL; FSSIA estimates

Exhibit 8: Key assumptions for our financial analysis of GUNKUL's hemp and cannabis venture

Cannabis	2021	2022E	2023E	2024E	Unit
Farming area	9	20	50	100	rai
Cannabis flower production	0	38,681	96,703	193,406	kg per year
Full spectrum production	0	2,089	5,222	10,444	kg per year
Cannabis CBD production	0	1,083	2,708	5,415	kg per year
Net profit	0	619	1,612	2,321	THB m
Assumptions	2022E				
Greenhouse per rai	1.0				greenhouse per rai
Cannabis trunk per greenhouse	1,776				trunk
Flower per trunk	0.3				kg
Crop per year	3.3				crop
Flower production	38,681				kg per annum
Conversion					
Flower	1,000				kg of flowers
Flower-to-full spectrum liquid	180				kg of full spectrum
Flower-to-CBD	80				kg of CBD (12%)
Dried cannabis flowers	45,000				THB/kg of flower
Full spectrum	100,000				THB/kg of full spectrum
Isolated distilled CBD	150,000				THB/kg of CBD
Investment cost					
Investment	5,000				THB/sqm
Sqm-to-rai ratio	1,600				sqm/rai
Investment per greenhouse	400				THB m
Extraction plant	300				THB m
Total investment	700				THB m

Sources: GUNKUL; FSSIA estimates

Exhibit 9: Financial analysis of GUNKUL's hemp and cannabis venture

Assumptions					Unit
Operating expense		100			THB m/year
Depreciation		140			THB m/year
Greenhouse		80			THB m/year
Extraction plant		60			THB m/year
2022E	Mixed (base case)	Dried flower	Full spectrum cannabis extract	CBD isolate	Unit
Selling price	4,487	45,000	100,000	150,000	THB/kg
Sales mix					
CBD isolate	35			100	%
Full spectrum cannabis extract	30		100		%
Dried flower	30	100			%
Sales volume					
CBD isolate	1,083			3,095	kg
Full spectrum cannabis extract	2,089		6,963		kg
Dried flower	11,604	38,681			kg
Financial forecasts	Mixed (base case)	Dried flower	Full spectrum cannabis extract	CBD isolate	Unit
Revenue	894	1,741	696	464	THB m
Gross profit	794	1,501	456	224	THB m
Interest expense	(20)	(20)	(20)	(20)	THB m
EBT	774	1,481	437	205	THB m
Tax expense	(155)	(296)	(87)	(41)	THB m
Net profit	619	1,185	349	164	THB m
Payback period	0.9	0.5	1.4	2.3	years

Sources: GUNKUL; FSSIA estimates

Thailand’s hemp product selling price structure

After the Thai government legalised the use of hemp and cannabis for public use, which includes own-use and commercial farming, CBD and full spectrum extractions, and as ingredients for F&B, pharmaceutical, and cosmetic products, GUNKUL, as one of the first movers to enter the HC industry, has been successfully growing and extracting CBD for commercial purposes in both the domestic and export markets.

To reduce the initial demand risk, GUNKUL has locked in long-term demand for CBD extracts and HC flowers via a long-term contract to provide soluble CBD, CBD extracts, and hemp leaves to Charoen Pokphand Foods (CPF TB, HOLD, TP THB28) and Black Canyon, one of Thailand’s leading coffee and food chains.

According to the [Thai Industry Hemp Trade Association \(TiHTA\)](#), there are lists of suggested prices for hemp products, including flowers grown via different approaches, leaves, roots, fibre, stalks, and seeds. While the suggested selling prices are not mandatory, they provide guidelines and the price benchmark for companies in the hemp value chain, which are more or less comparable or cheaper than the selling prices in other overseas markets, based on our estimate.

Exhibit 10: Suggested selling prices of hemp flowers by TiHTA

Greenhouse		
	Price (THB/kg)	
CBD level	Min	Max
Over 12%	22,000	22,000
10-11.9%	15,000	18,000
8-9.9%	10,000	13,000
6.0-7.9%	7,000	9,000
Indoor		
	Price (THB/kg)	
CBD level	Min	Max
Over 14%	45,000	50,000
12-13.9%	40,000	42,000
10-11.9%	35,000	38,000
8-9.9%	30,000	33,000
Dried hemp leaves		
	Price (THB/kg)	
Plantation form	Min	Max
Indoor	3,000	15,000
Green House	1,000	10,000
Outdoor	300	2,000

Source: [Thai Industrial Hemp Trade Association](#)

Exhibit 12: Hemp flowers



Source: [Thai Industrial Hemp Trade Association](#)

Exhibit 11: Suggested selling prices of hemp trees, fibre, stalks, roots, and seeds, by TiHTA

Dried hemp (outdoor)		
	Price (THB/kg)	
	Min	Max
Fresh hemp tree	20	20
Dry hemp tree	80	100
Fibre	1,000	1,000
Stalk	300	300
Hemp root		
	Price (THB/kg)	
	Organic	Non-organic
Fresh	700-1,200	250-500
Dry	2,500-4,000	1,000-2,000
Hemp seeds		
	Price (THB/kg)	
	Min	Max
Outdoor	800	1,500
Grade A (clean and washed)	1,500	1,500
Grade B	700	800

Source: [Thai Industrial Hemp Trade Association](#)

Exhibit 13: Hemp leaves



Source: [Thai Industrial Hemp Trade Association](#)

Exhibit 14: Hemp trees, fibre, and stalks



Source: [Thai Industrial Hemp Trade Association](#)

Exhibit 15: Hemp root



Source: [Thai Industrial Hemp Trade Association](#)

Exhibit 16: Hemp seeds



Source: [Thai Industrial Hemp Trade Association](#)

Exhibit 17: Hemp processing




Source: [Thai Industrial Hemp Trade Association](#)

Global selling price structure for hemp products


In 1Q22, according to [Green Growth CPAs](#), the aggregate national price of wholesale flowers for 18 states differing by grow type in the US market has continued its downtrend, standing at USD1,237 per pound (lb) in 1Q22, down 9% q-q and 18% y-y. The main reasons for the price fall include weak demand, as consumers are feeling the pinch of higher inflation, and the rising supply in the US market.

Exhibit 18: Hemp benchmark wholesale price by grow type as of 1Q22



Source: [GreenGrowthCPAs.com](#)


Exhibit 19: State level spot pricing (trailing 4-week average) for wholesale hemp flowers



Source: [GreenGrowthCPAs.com](#)


CBD price in the US market. While the wholesale prices in the major American hemp markets have continued to decline, the prices remain high above USD800/lb, with the highest price in Illinois at over USD3,600/lb down to USD800/lb in Oregon state. Since the enactment of the Agriculture Improvement Act by the US federal government to remove the low-tetrahydrocannabinol (THC) cannabis and cannabis-derived products from the marijuana stipulation by the Controlled Substances Act, the now-legal cannabinoid-derived products for consumer purchase and sale throughout the US have driven the demand for cannabis-derived products, growing significantly to become the world’s largest CBD market in 2021.

Exhibit 20: Hemp cannabinoid guide



Source: Green Unicorn Farms

Exhibit 21: State level spot pricing for wholesale hemp flowers




Sources: [GreenGrowthCPAs.com](#)

Global CBD market size. According to Global Market Insight, the global cannabidiol market size accounted for USD12.8b in 2021 and is estimated to grow at a 21.7% CAGR between 2022 and 2028 to reach USD56.3b in 2028. Rising awareness of the health benefits of CBD and its effectiveness in pain management & various other treatments is propelling the CBD industry's growth.

CBD is a chemical compound obtained from marijuana and hemp plants and is commonly used for medical purposes, including treating pain, anxiety, muscle disorders (dystonia), Crohn's disease, Parkinson's disease and many other medical conditions. Hence, CBD is gaining widespread popularity across different regions.


North America was the largest market in the past, on account of the legalisation of CBD for medical and research purposes on the continent, which led to rapidly increasing sales. The status of the product as a natural phytocompound, its strong promotion by companies as a lifestyle and wellness product, the launch of CBD-based pharmaceuticals, such as Sativex and Epidiolex, and the wide availability of various products containing this compound are further expected to propel the sale of CBD in the region in the coming years.

Exhibit 22: Global CBD market breakdown by region, 2021



Source: [Global Market Insight](#)


Exhibit 23: CBD market by product (2021 vs 2028E) in USD m



Source: [Global Market Insight](#)

CBD market by product. According to Global Market Insight, by product, the CBD market is segmented into oils, tinctures, suppositories, transdermal patches, isolates, tablets, capsules, vape oils, creams and roll-ons, CBD inhalers and others. The oil segment accounted for over USD3.1b in revenue in 2021. CBD oil is made by extracting CBD from the cannabis plant and is commonly used in pain-related disorders owing to its extensive benefits.

Exhibit 24: CBD market size



Source: [Global Market Insight](#)

Exhibit 25: Global CBD oil market in 2019




Source: [Prescient & Strategic Intelligence](#)

As an increasing number of people have adopted a sedentary lifestyle involving limited muscular movement, it has led to an increasing prevalence of chronic pain among adults. The significant disease burden of chronic pain is identified on a global level, and it is estimated that nearly 1 in 10 adults suffer from chronic pain, according to Global Market Insight. Hence, with such concerning statistics and regulatory authorities addressing the consumption of CBD, the market is anticipated to witness a significant surge in the coming years.

In the coming years, the fastest growth in the CBD oil market should be experienced by the tincture category, under segmentation by product. This is primarily credited to the growing demand for medical-use CBD by patients suffering from depression, anxiety, movement disorders, and pain.


Moreover, Global Market Insight notes that the popularity of CBD tinctures is also rising among recreational users, whose number is expected to burgeon in the coming years. Other reasons behind the high demand for tinctures are that they are easily available via numerous distribution channels, including pharmacies, e-commerce websites, and retail and specialty stores, and have less-potent effects than other forms of the cannabinoid. Similarly, its administration route, i.e. sublingual, which involves placing the tincture under the tongue, is favoured over inhalation.

Exhibit 26: Extracted compounds from the cannabis plant



Source: [CBDAssist](#)

Exhibit 27: Full spectrum vs Broad spectrum vs Isolate



Source: [CBDAssist](#)

Three types of CBD. According to CBDAssist, For CBD oil products, there are three main classifications: Full Spectrum CBD, Broad Spectrum CBD, and CBD Isolate, each with great importance and varying roles. The three may equally be vital when it comes to providing therapeutic effects and relief, but each classification is prepared with a specific purpose in mind.


In general, cannabinoids enter the human body and directly interact with the body's own receptors called the Endocannabinoid System. Each type of cannabinoid has a distinct effect on humans and they also come with their own unique effect varying from case to case.

From the Cannabis plant, cannabinoids are extracted through different methods but the most widely used extraction method is known as CO2 extraction, where CBD is harvested along with other compounds which are also naturally present. Numerous other naturally occurring compounds in plants such as terpenes, flavonoids, essential oils, and even other plant parts can be extracted from the Cannabis plant, especially when using a highly organic and natural extracting method such as CO2 extraction.

Depending on the end product or the specific amount of CBD that is particularly needed, medical companies and laboratories can curate the cannabinoid profile and composition that is targeted. They can opt for pure CBD, CBD mixed with THC, or even have CBD with all its other natural compounds retained.

With the process and the CBD content in mind, the three classifications differ in what actually composes the CBD profile and which compounds are retained and which ones are removed. Hence, the question of whether to choose CBD isolate, full spectrum, or broad spectrum should be considered.

Exhibit 28: CBD isolate



Source: [CBDAssist](#)

CBD isolate: Known as the purest form possible of the cannabinoid compound, CBD isolate only contains CBD itself, with all other compounds removed during the extraction process. Typically, hemp is used to extract this specific type of CBD as hemp is known to have very low and close to non-existent levels of THC.


Without THC and minus all other natural compounds like flavonoids, essential oils, and terpenes, CBD isolate is generally considered to be safe for use, especially for those who are new to CBD and are just trying out its medicinal value. It is tasteless and odourless, purely containing only CBD in its purest form. With the absence of THC, individuals can benefit from its therapeutic qualities without any psychoactive side effects and without the risk of testing positive on drug tests, according to CBDAssist.

However, CBD isolate only has the one cannabinoid, Cannabidiol, and therefore its effects are not as fully potent as the other two types (full spectrum and broad spectrum). For prolonged use or for severe conditions, CBD isolate will not be able to produce highly effective therapeutic results as the full spectrum and broad spectrum CBD could deliver on a case to case basis.

CBDAssist notes that CBD isolate is ideally recommended to be used by:

- First-time users of CBD and those sensitive to strong odours and flavours;
- Users who need specifically high doses of CBD only;
- Users who regularly take drug screening tests and who might live in states with strict THC regulations and Cannabis laws;
- Users who are highly sensitive to THC and its unwanted side effects.

Exhibit 29: Cannabis molecular structure



Source: [Masaki](#)

Full spectrum: Full spectrum CBD contains all compounds in the Cannabis plant, which are all naturally occurring in its rawest form. Along with Cannabidiol, other cannabinoids and compounds are extracted from the plant such as terpenes, flavonoids, essential oils, and even tiny plant parts which can all work together to produce potent therapeutic benefits for the patient. With each compound taken alongside the other naturally occurring compounds present in the cannabis plant, full spectrum CBD has an “entourage effect”, wherein the body’s receptors can maximise absorption of the cannabinoids as well as the other natural compounds. With each dynamic component complimenting the others, full spectrum CBD can be highly effective in providing relief since the natural profile is almost preserved even after extraction, according to CBDAssist.


One of the main drawbacks of full spectrum CBD is the presence of THC as it is the compound known for its psychoactive effects and other unwanted Cannabis plant side effects. THC may show up in a drug test, which in turn could have legal implications.

Also, since full spectrum CBD retains most of its natural compounds and profiles, it has a strong distinct odour and potent natural flavour. It might be too much to handle for people with sensitivity to odours, easily nauseated patients, or even for those who are new to CBD products.

CBDAssist notes that full spectrum CBD products are ideal to be used by:


- Those who need a more potent CBD to experience maximum therapeutic effects, especially if using the two other CBD types aren’t enough to provide relief;
- Those who have used THC before (e.g. marijuana smokers) and are accustomed to its effects;
- Those with a specially prescribed or recommended THC to CBD ratio for high effectivity.

Exhibit 30: Full spectrum CBD



Sources: [CBDAssist](#)

Exhibit 31: Broad spectrum CBD



Sources: [CBDAssist](#)

Broad spectrum: Like a mix of full spectrum CBD and CBD isolate, broad spectrum CBD offers the best of both types when it comes to its special composition. Similar to full spectrum, broad spectrum has retained all naturally occurring compounds to achieve the enhanced “entourage effect” of cannabinoids when taken with other compounds. However, like CBD isolate, broad spectrum has THC completely removed to get rid of the unwanted psychoactive side effects and to also be risk-free when dealing with regular drug screenings. Basically, broad spectrum is full spectrum without THC.

Using broad spectrum CBD means getting to benefit from the two other types without the risks involved when dealing with THC. Broad spectrum CBD, however, has just recently been introduced which translates to having fewer scientific studies done to prove its effectivity vs the two other more established types. Availability is also a drawback as it isn’t as easily accessible as CBD isolate and full spectrum CBD, according to CBDAssist.

Because of its unique blend and great therapeutic qualities, broad spectrum CBD is ideal for:

- Those with conditions that are not responsive to CBD isolate alone;
- Those who are first-time users of CBD and are hesitant to try THC;
- Those who live in areas with THC restrictions and who regularly undergo drug test screenings for THC.

Though each type has its own unique composition, its own distinct profile, and its own specific effects on the human body, all three are equally useful depending on the user. Choosing which one is to be used may be an objective decision based on the individual's personal preference, condition, and therapeutic needs.

As it is getting recognition and acceptance worldwide, cannabinoid studies are getting more and more popular since it has been proven to hold so much potential in terms of its therapeutic qualities. With the existing studies coupled with more advanced research and on-going experiments, CBD products may be able to achieve their full potential as an essential game-changer in the field of medicine and in the lives of countless people.

Exhibit 32: SNNP's snack mixed with cannabis leaf



Source: SNNP

Exhibit 33: CBD application forms and labels



Source: [Label Value](#)

CBD applications: CBD has multiple uses in many forms, which have to be properly labelled to ensure that consumers fully understand and accurately use the CBD-contained products for their purposes. In general, there are six forms of CBD-contained products – tinctures, baked goods, gummies, beverages, supplements, and balms & lotions.

Food or supplement? CBD products need to be clearly determined for their qualities as food or supplement. If the product qualifies as a food or drink, it will be subject to the stipulations and regulations outlined by the Food and Drug Administration (FDA) – the FDA in Thailand is under the Ministry of Public Health.

In 2022 onward, we believe a host of CBD-contained products will be on the market for consumers to choose following the FDA's legalisation of the use of CBD and cannabis for F&B, pharmaceutical, and cosmetic purposes since 9 Jun-22.

In Thailand, there are a number of cannabis-related products already being marketed to consumers. One of the first-mover products that has been highly successful is the snack mixed with cannabis leaf produced by Srinanaporn Marketing (SNNP TB, BUY, TP THB20), one of Thailand's leading snack producers.

Cannabis and CBD have been used for medical purposes in Thailand for a few years now. In 2019, Thailand's first full-time clinics dispensing cannabis oil for medical treatment were opened. A cannabis flagship clinic under the management of Public Health Management handed over free cannabis oil to over 1,000 patients in a suburb of Bangkok since it opened its doors in 2019.

The government clearly intended to promote the licensed use of marijuana products to relieve the symptoms of a range of ailments even before the official legalisation of cannabis and hemp-related products for the public.

While the application of marijuana and CBD produced from hemp and cannabis remains regulated, the government is now promoting its use under certain conditions, allowing patients to seek medical treatment via marijuana, cannabis, and hemp.

CBD benefits. Cannabis has been used to treat pain for quite some time, and more recently various studies have stated that certain components of cannabis, including CBD, are responsible for pain-relieving effects. For instance, according to a study from Michigan University in 2021, out of 878 patients with fibromyalgia, 72% were reportedly using CBD to manage their pain. CBD helped to decrease their pain compared to other drug therapies which were less effective. Thus, the widespread use of CBD products along with changing consumer opinion has increased the adoption rate of CBD products, thereby propelling market statistics.

Legalisation of CBD to power hemp and cannabis market in Thailand

The major force taking the market toward a potential boom is the legalisation of the compound in numerous countries. Since the receipt of legal approval of CBD in Canada and the US, several countries have followed suit and many more are doing the same. Currently, a number of nations in Latin America, Asia-Pacific, and Europe have allowed the partial or complete sale of CBD-containing products. These include Norway, the UK, Japan, Spain, Thailand, South Korea, Brazil, Mexico, and South Africa.

Though regulations vary, the cultivation of cannabis and downstream production is rising across nations, which should create interest among prospective customers. This is helping governments to create additional jobs and gain revenue from the sale and licensing of CBD-containing products.

Additionally, with countries giving the regulatory approval to hemp and marijuana, investing in mass production and commercialisation, and bettering their supply and logistics chain, the demand for the compound and related products should be bolstered in the near future.

Thailand's development in the CBD industry. On 9 Jun-22, according to [Vice.com](https://www.vice.com), the Thai government legalised cannabis growing for the public, transforming Thailand into the region's most progressive country on the drug as the government attempts to spark a green rush and capitalise on the industry. Thai people are now free to grow unlimited amounts of cannabis, as a law ratified in Feb came into effect on 9 Jun-22. The plant has officially been removed from the country's narcotics list, although smoking marijuana in public is still an offense.

Crucially, cannabis extracts containing more than 0.2% THC – the main psychoactive element in cannabis that elicits the "high" – remain outlawed. So, while anyone is free to own and cultivate as many cannabis plants as they like – and are encouraged to register their crops on the FDA's Plookganja app – consuming what they produce remains technically illegal. Lawmakers are still in the midst of deliberating a bill regulating the sale and consumption of cannabis, though it's unclear under what circumstances this will permit people to consume the cannabis they produce.

GUNKUL as one of the first movers in Thailand's cannabis market. According to Prescient & Strategic Intelligence, the key trend being witnessed in the CBD oil market is the increasing investment volume across the value chain of the product. With the deregulation of hemp and CBD in several countries, companies are looking at it as a lucrative business area. Organisations are stepping up efforts to license the production of marijuana and hemp, set up downstream distribution channels, invest in research and development, develop the supply chain, enter new geographies, and increase the output of different products containing this cannabinoid.

All these steps are aimed at ensuring brand equity in the early-stage market, garnering a loyal customer base, and securing consistent revenue streams. Since 2018, major players in the global CBD oil market, Aurora Cannabis Inc., Canopy Growth Corporation, and Aphria Inc. have implemented a number of strategies to raise the sale of cannabidiol and increase their revenue. These include launching new products, acquiring licenses, and entering into collaborations with omni-channel marketing organisations, dispensaries, pharmacies, and specialty retailers. Similarly, market players are investing in enhancing their supply chain, to meet the demand for cannabidiol-related products.

Exhibit 34: Gun-Chaya clinics owned by THCG and GUNKUL **Exhibit 35: Interior of Gun-Chaya clinic**



Source: GUNKUL



Source: GUNKUL

Medical diseases for which marijuana and cannabis use is approved by the Thai government. According to [Cannabis for Thailand](#), the list of approved diseases for which marijuana and cannabis can be used for relief include – addiction withdrawal symptoms, allergies, Alzheimer's, anorexia, bedsores, bone fractures, bronchitis, cancer, cerebral palsy (children), chemotherapy, cirrhosis of liver, concussion, Crohn's disease, demyelinating disease, diabetes, epilepsy, glaucoma, hemorrhoids, HIV/AIDS, hydrocephalus, hypertension (high blood pressure), inflammation, lupus, lymphoma, migraine, menstrual cramps, obesity, ODC/ADHD, opiate addiction, pain, paralysis, Parkinson's disease, PTSD (Post-Traumatic Stress Disorder), reaction stress, rheumatism, schizophrenia, stroke, and Tourette's syndrome.

GUNKUL has invested THB250m to acquire a 50% stake in THCG group, one of the operators in the hemp and cannabis business with a full value chain of cultivation, extraction, and production of hemp and CBD-related products in the F&B and medical industries.

"Gun-Chaya" clinic, owned by THCG, is a clinic licensed to dispense the hemp, cannabis, and CBD products, including herbs, oils, medicines, aroma therapy, and treatment for insomnia, office syndrome, and migraines. GUNKUL plans to leverage THCG's assets to open up and grow its hemp and cannabis venture in 2022 onward, according to management.

EPS and target price revisions

We revise down our EPS forecasts for 2022-24 due to our assumption of a lower production level of hemp flowers and related derivative products due to the longer-than-expected delay in the legalisation of the use and consumption of hemp-related products for the public and our more conservative view on the initial sales volumes and margins for the hemp business. In essence, we cut our net profit forecasts for the hemp venture by 63%/3.9%/16% for 2022-24 to reflect our assumption of lower hemp flower production.

We lower our SoTP-based TP from THB8.2 to THB6.8 to reflect our lower EPS assumptions. We think GUNKUL's net profit growth will be driven and transformed by its hemp venture in 2022-24, which we project to grow from THB0.6b in 2022 to THB2.3b in 2024.

Exhibit 36: Key changes in assumptions

	Current			Previous			Change		
	2022E (THB m)	2023E (THB m)	2024E (THB m)	2022E (THB m)	2023E (THB m)	2024E (THB m)	2022E (%)	2023E (%)	2024E (%)
Revenue	10,482	12,555	12,882	12,315	13,048	15,118	(14.9)	(3.8)	(14.8)
Gross profit	5,423	7,258	7,573	7,257	7,751	9,809	(25.3)	(6.4)	(22.8)
Operating profit	3,060	4,632	4,931	4,710	5,076	6,943	(35.0)	(8.7)	(29.0)
Net profit	2,273	3,622	3,938	3,860	4,067	5,906	(41.1)	(10.9)	(33.3)
EPS (THB/share)	0.26	0.41	0.44	0.43	0.46	0.66	(41.1)	(10.9)	(33.3)
Key assumptions									
EPC revenue (THB m)	1,000	1,200	1,000	1,000	1,200	1,000	0.0	0.0	0.0
Trading revenue (THB m)	1,483	1,483	1,483	1,483	1,483	1,483	0.0	0.0	0.0
Cannabis flower production (kg)	11,604	29,011	58,022	58,022	58,022	116,044	(80.0)	(50.0)	(50.0)
Cannabis spectrum production (kg)	2,089	5,222	10,444	10,444	10,444	20,888	(80.0)	(50.0)	(50.0)
Cannabis CBD production (kg)	1,083	2,708	5,415	5,415	5,415	10,831	(80.0)	(50.0)	(50.0)
Cannabis net profit (THB m)	619	1,612	2,321	1,677	1,679	2,762	(63.1)	(3.9)	(16.0)

Sources: GUNKUL; FSSIA estimates

Exhibit 37: SoTP-based valuation

Cost of equity assumptions	(%)		Cost of debt assumptions	(%)
Risk free rate	2.3		Pretax cost of debt	3.5
Market risk premium	8.5		Marginal tax rate	20.0
Stock beta	0.80			
Cost of equity, Ke	9.1		Net cost of debt, Kd	2.7
Weight applied	20.0		Weight applied	80.0
WACC (%)	4.0			
Sum-of-part valuation estimate	(THB m)	(THB/share)	Comments	
EPC	3,900	0.4	20x FY21E P/E, discount to industry average of 22x	
Trading	1,898	0.2	20x FY21E P/E, discount to industry average of 22x	
Solar power	18,022	2.0	DCF WACC 4%	
Wind power	20,936	2.4	DCF WACC 4%	
Gas engine power	535	0.1	DCF WACC 4%	
Cannabis	35,474	4.0	22x FY24E P/E	
Net cash	(21,740)	(2.4)	Net cash on hand at end 2022E	
Residual ordinary equity	59,025	6.6		

Sources: GUNKUL; FSSIA estimates

Financial Statements

Gunkul Engineering

Profit and Loss (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Revenue	8,649	9,318	10,482	12,555	12,882
Cost of goods sold	(4,167)	(4,352)	(5,059)	(5,298)	(5,308)
Gross profit	4,482	4,967	5,423	7,258	7,573
Other operating income	-	-	-	-	-
Operating costs	(955)	(972)	(1,198)	(1,441)	(1,438)
Operating EBITDA	3,527	3,995	4,225	5,817	6,135
Depreciation	(1,353)	(1,542)	(1,165)	(1,185)	(1,205)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	2,174	2,453	3,060	4,632	4,931
Net financing costs	(915)	(860)	(842)	(854)	(796)
Associates	73	218	208	97	97
Recurring non-operating income	150	527	301	236	236
Non-recurring items	(88)	320	0	0	0
Profit before tax	1,321	2,439	2,519	4,014	4,371
Tax	(119)	(188)	(139)	(275)	(315)
Profit after tax	1,202	2,252	2,380	3,739	4,056
Minority interests	(13)	(22)	(107)	(117)	(118)
Preferred dividends	0	0	0	0	0
Other items	-	-	-	-	-
Reported net profit	1,189	2,229	2,273	3,622	3,938
Non-recurring items & goodwill (net)	88	(320)	0	0	0
Recurring net profit	1,277	1,909	2,273	3,622	3,938
Per share (THB)					
Recurring EPS *	0.14	0.21	0.26	0.41	0.44
Reported EPS	0.13	0.25	0.26	0.41	0.44
DPS	0.14	0.18	0.24	0.24	0.24
Diluted shares (used to calculate per share data)	8,883	8,883	8,883	8,883	8,883
Growth					
Revenue (%)	21.8	7.7	12.5	19.8	2.6
Operating EBITDA (%)	(10.6)	13.2	5.8	37.7	5.5
Operating EBIT (%)	(22.6)	12.8	24.8	51.4	6.4
Recurring EPS (%)	(50.8)	49.5	19.1	59.3	8.7
Reported EPS (%)	(53.8)	87.5	2.0	59.3	8.7
Operating performance					
Gross margin inc. depreciation (%)	36.2	36.8	40.6	48.4	49.4
Gross margin of key business (%)	35.2	40.2	40.6	48.4	49.4
Operating EBITDA margin (%)	40.8	42.9	40.3	46.3	47.6
Operating EBIT margin (%)	25.1	26.3	29.2	36.9	38.3
Net margin (%)	14.8	20.5	21.7	28.8	30.6
Effective tax rate (%)	3.4	8.5	6.0	7.0	7.4
Dividend payout on recurring profit (%)	94.6	83.7	93.8	58.9	54.1
Interest cover (X)	2.5	3.5	4.0	5.7	6.5
Inventory days	56.5	60.7	65.8	71.6	73.2
Debtor days	82.9	84.8	52.9	47.5	49.9
Creditor days	137.1	171.3	136.8	148.8	152.1
Operating ROIC (%)	6.7	(1.7)	(2.1)	(3.2)	(3.4)
ROIC (%)	5.6	(1.6)	(1.8)	(2.6)	(2.8)
ROE (%)	11.1	15.0	16.9	24.9	24.3
ROA (%)	4.8	4.0	5.3	8.3	8.6
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)					
Manufacturing and selling of equipment for electrical systems	1,188	1,500	1,000	1,200	1,000
Generating and selling electricity	5,031	4,888	6,158	6,691	6,234
Construction service	2,500	3,000	2,500	2,500	2,500
Maintenance service	145	145	145	145	145

Sources: Gunkul Engineering; FSSIA estimates

Financial Statements

Gunkul Engineering

Cash Flow (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Recurring net profit	1,277	1,909	2,273	3,622	3,938
Depreciation	1,353	1,542	1,165	1,185	1,205
Associates & minorities	73	218	208	97	97
Other non-cash items	-	-	-	-	-
Change in working capital	(4,192)	(516)	(170)	(587)	(207)
Cash flow from operations	(1,489)	3,153	3,475	4,317	5,032
Capex - maintenance	(1,353)	(1,542)	(456)	(481)	(506)
Capex - new investment	(2,376)	(407)	(44)	(19)	(6)
Net acquisitions & disposals	165	(267)	0	0	0
Other investments (net)	(707)	(2,996)	208	97	97
Cash flow from investing	(4,271)	(5,213)	(292)	(403)	(415)
Dividends paid	0	0	(1,599)	(2,132)	(2,132)
Equity finance	0	426	0	0	0
Debt finance	4,449	(2,024)	(2,968)	1,821	(1,179)
Other financing cash flows	1,486	994	(309)	(77)	(64)
Cash flow from financing	5,935	(604)	(4,876)	(388)	(3,375)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	174	(2,663)	(1,693)	3,525	1,242
Free cash flow to firm (FCFF)	(4,848.97)	(1,088.95)	4,059.39	4,768.19	5,484.63
Free cash flow to equity (FCFE)	173.91	(3,089.56)	(93.92)	5,656.87	3,374.07

Per share (THB)

FCFF per share	(0.65)	(0.15)	0.55	0.64	0.74
FCFE per share	0.02	(0.42)	(0.01)	0.76	0.45
Recurring cash flow per share	0.30	0.41	0.41	0.55	0.59

Balance Sheet (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Tangible fixed assets (gross)	30,754	31,688	32,188	32,688	33,188
Less: Accumulated depreciation	(3,811)	(5,152)	(6,317)	(7,502)	(8,706)
Tangible fixed assets (net)	26,943	26,536	25,871	25,186	24,482
Intangible fixed assets (net)	3,578	3,463	3,463	3,463	3,463
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	1,566	1,833	1,833	1,833	1,833
Cash & equivalents	4,392	1,729	36	3,562	4,804
A/C receivable	2,864	1,466	1,570	1,696	1,825
Inventories	637	809	1,015	1,063	1,065
Other current assets	3,889	3,563	4,008	4,801	4,926
Current assets	11,782	7,567	6,630	11,122	12,620
Other assets	2,163	3,087	3,087	3,087	3,087
Total assets	46,032	42,485	40,884	44,691	45,485
Common equity	12,350	13,122	13,796	15,286	17,092
Minorities etc.	125	162	268	385	503
Total shareholders' equity	12,475	13,283	14,064	15,671	17,595
Long term debt	18,793	18,630	15,662	17,483	16,303
Other long-term liabilities	1,781	1,518	1,518	1,518	1,518
Long-term liabilities	20,574	20,149	17,181	19,001	17,822
A/C payable	2,404	1,681	2,110	2,209	2,214
Short term debt	7,975	6,114	6,114	6,114	6,114
Other current liabilities	2,604	1,258	1,415	1,695	1,739
Current liabilities	12,983	9,054	9,639	10,019	10,067
Total liabilities and shareholders' equity	46,032	42,485	40,884	44,691	45,485
Net working capital	2,383	2,898	3,069	3,656	3,863
Invested capital	36,632	37,817	37,323	37,225	36,728

* Includes convertibles and preferred stock which is being treated as debt

Per share (THB)

Book value per share	1.39	1.48	1.55	1.72	1.92
Tangible book value per share	0.99	1.09	1.16	1.33	1.53

Financial strength

Net debt/equity (%)	179.4	173.3	154.6	127.8	100.1
Net debt/total assets (%)	48.6	54.2	53.2	44.8	38.7
Current ratio (x)	0.9	0.8	0.7	1.1	1.3
CF interest cover (x)	3.8	(2.1)	0.9	7.6	5.2

Valuation	2020	2021	2022E	2023E	2024E
Recurring P/E (x) *	38.3	25.6	21.5	13.5	12.4
Recurring P/E @ target price (x) *	45.9	30.7	25.8	16.2	14.9
Reported P/E (x)	41.1	21.9	21.5	13.5	12.4
Dividend yield (%)	2.5	3.3	4.4	4.4	4.4
Price/book (x)	4.0	3.7	3.5	3.2	2.9
Price/tangible book (x)	5.6	5.1	4.7	4.1	3.6
EV/EBITDA (x) **	20.2	18.0	16.8	11.9	10.9
EV/EBITDA @ target price (x) **	23.0	20.5	19.1	13.6	12.5
EV/invested capital (x)	1.9	1.9	1.9	1.9	1.8

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Gunkul Engineering; FSSIA estimates

Corporate Governance report of Thai listed companies 2021

EXCELLENT LEVEL – Score range 90-100										
AAV	BCPG	CPALL	GCAP	K	MSC	PLANET	SAMART	SPI	THRE	TVD
ADVANC	BDMS	CPF	GFPT	KBANK	MST	PLAT	SAMTEL	SPRC	THREL	TVI
AF	BEM	CPI	GGC	KCE	MTC	PORT	SAT	SPVI	TIPCO	TVO
AH	BGC	CPN	GLAND	KKP	MVP	PPS	SC	SSSC	TISCO	TWPC
AIRA	BGRIM	CRC	GLOBAL	KSL	NCL	PR9	SCB	SST	TK	U
AKP	BIZ	CSS	GPI	KTB	NEP	PREB	SCC	STA	TKT	UAC
AKR	BKI	DDD	GPSC	KTC	NER	PRG	SCCC	STEC	TMT	UBIS
ALT	BOL	DELTA	GRAMMY	LALIN	NKI	PRM	SCG	STI	TNDT	UV
AMA	BPP	DEMCO	GULF	LANNA	NOBLE	PROUD	SCGP	SUN	TNITY	VGI
AMATA	BRR	DRT	GUNKUL	LH	NSI	DRS	SCM	SUSCO	TOA	VIH
AMATAV	BTS	DTAC	HANA	LHFG	NVD	PSL	SDC	SUTHA	TOP	WACOAL
ANAN	BTW	DUSIT	HARN	LIT	NWR	PTG	SEAFCO	SVI	TPBI	WAVE
AOT	BWG	EA	HMPRO	LPN	NYT	PTT	SEAOIL	SYMC	TQM	WHA
AP	CENTEL	EASTW	ICC	MACO	OISHI	PTTEP	SE-ED	SYNTEC	TRC	WHAUP
ARIP	CFRESH	ECF	ICHI	MAJOR	OR	PTTGC	SELIC	TACC	TRU	WICE
ARROW	CHEWA	ECL	III	MAKRO	ORI	PYLON	SENA	TASCO	TRUE	WINNER
ASP	CHO	EE	ILINK	MALEE	OSP	Q-CON	SHR	TCAP	TSC	ZEN
AUCT	CIMBT	EGCO	ILM	MBK	OTO	QH	SIRI	TEAMG	TSR	
AWC	CK	EPG	INTUCH	MC	PAP	QTC	SIS	TFMAMA	TSTE	
AYUD	CKP	ETC	IP	MCOT	PCSGH	RATCH	SITHAI	TGH	TSTH	
BAFS	CM	FPI	IRPC	METCO	PDG	RS	SMK	THANA	TTA	
BANPU	CNT	FPT	ITEL	MFEC	PDJ	S	SMPC	THANI	TTB	
BAY	COM7	FSMART	IVL	MINT	PG	S & J	SNC	THCOM	TTCL	
BBL	COMAN	GBX	JSP	MONO	PHOL	SAAM	SONIC	THG	TTW	
BCP	COTTO	GC	JWD	MOONG	PLANB	SABINA	SPALI	THIP	TU	
VERY GOOD LEVEL – Score range 80-89										
2S	ASIMAR	CHOW	FLOYD	IT	LOXLEY	OCC	RPC	SKY	TCC	TVT
7UP	ASK	CI	FN	ITD	LRH	OGC	RT	SLP	TCMC	TWP
ABICO	ASN	CIG	FNS	J	LST	PATO	RWI	SMIT	TEAM	UEC
ABM	ATP30	CMC	FORTH	JAS	M	PB	S11	SMT	TFG	UMI
ACE	B	COLOR	FSS	JCK	MATCH	PICO	SA	SNP	TFI	UOBKH
ACG	BA	CPL	FTE	JCKH	MBAX	PIMO	SAK	SO	TIGER	UP
ADB	BAM	CPW	FVC	JMART	MEGA	PJW	SALEE	SORKON	TITLE	UPF
AEONTS	BC	CRD	GEL	JMT	META	PL	SAMCO	SPA	TKN	UPOIC
AGE	BCH	CSC	GENCO	KBS	MFC	PM	SANKO	SPC	TKS	UTP
AHC	BEC	CSP	GJS	KCAR	MGT	PMTA	SAPPE	SPCG	TM	VCOM
AIT	BEYOND	CWT	GYT	KEX	MICRO	PPP	SAWAD	SR	TMC	VL
ALL	BFIT	DCC	HEMP	KGI	MILL	PPP	SCI	SRICHA	TMD	VPO
ALLA	BJC	DCON	HPT	KIAT	MITSIB	PRIME	SCN	SSC	TMI	VRANDA
ALUCON	BJCHI	DHOUSE	HTC	KISS	MK	PRIN	SCP	SSF	TMILL	WGE
AMANAHA	BLA	DOD	HYDRO	KOOL	MODERN	PRINC	SE	STANLY	TNL	WIJK
AMARIN	BR	DOHOME	ICN	KTIS	MTI	PSG	SFLEX	STGT	TNP	WP
APCO	BROOK	DV8	IFS	KUMWEL	NBC	PSTC	SFP	STOWER	TOG	XO
APCS	CBG	EASON	IMH	KUN	NCAP	PT	SFT	STPI	TPA	XPG
APURE	CEN	EFORL	IND	KWC	NCH	QLT	SGF	SUC	TPAC	YUASA
AQUA	CGH	ERW	INET	KWM	NETBAY	RBF	SIAM	SWC	TPCS	
ASAP	CHARAN	ESSO	INSET	L&E	NEX	RCL	SINGER	SYNEX	TPS	
ASEFA	CHAYO	ESTAR	INSURE	LDC	NINE	RICHY	SKE	TAE	TRITN	
ASIA	CHG	ETE	IRC	LEO	NRF	RML	SKN	TAKUNI	TRT	
ASIAN	CHOTI	FE	IRCP	LHK	NTV	ROJNA	SKR	TBSP	TSE	
GOOD LEVEL – Score range 70-79										
A	BGT	CITY	GIFT	JTS	MDX	PK	SGP	SUPER	TQR	YGG
AI	BH	CMAN	GLOCON	JUBILE	MJD	PLE	SICT	SVOA	TTI	ZIGA
AIE	BIG	CMO	GREEN	KASET	MORE	PPM	SIMAT	TC	TYCN	
AJ	BLAND	CMR	GSC	KCM	MUD	PRAKIT	SISB	TCCC	UKEM	
ALPHAX	BM	CPT	GTB	KK	NC	PRAPAT	SK	THMUI	UMS	
AMC	BROCK	CRANE	HTECH	KKC	NDR	PRECHA	SMART	TNH	UNIQ	
APP	BSBM	CSR	HUMAN	KWI	NFC	PTL	SOLAR	TNR	UPA	
AQ	BSM	D	IHL	KYE	NNCL	RJH	SPACK	TOPP	UREKA	
ARIN	BTNC	EKH	IIG	LEE	NOVA	RP	SPG	TPCH	VIBHA	
AS	BYD	EMC	INGRS	LPH	NPK	RPH	SQ	TPIPL	W	
AU	CAZ	EP	INOX	MATI	NUSA	RSP	SSP	TIPIP	WIN	
B52	CCP	F&D	JAK	M-CHAI	PAF	SABUY	STARK	TPLAS	WORK	
BEAUTY	CGD	FMT	JR	MCS	PF	SF	STC	TPOLY	WPH	

Disclaimer:

The disclosure of the survey results of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey results may be changed after that date. FSS International Investment Advisory Company Limited does not confirm nor certify the accuracy of such survey results.

* CGR scoring should be considered with news regarding wrong doing of the company or director or executive of the company such unfair practice on securities trading, fraud, and corruption SEC imposed a civil sanction against insider trading of director and executive

Sources: Thai Institute of Directors Association (IOD); FSSIA's compilation; data as of 26 October 2021

Anti-corruption Progress Indicator

CERTIFIED										
2S	BCH	CPALL	GC	K	MFC	PE	QLT	SNP	THCOM	TU
7UP	BCP	CPF	GCAP	KASET	MFEC	PG	QTC	SORKON	THIP	TVD
ADVANC	BCPG	CPI	GEL	KBANK	MILL	PHOL	RATCH	SPACK	THRE	TVI
AF	BE8	CPN	GFPT	KBS	MINT	PK	RML	SPALI	THREL	TVO
AI	BEYOND	CSC	GGC	KCAR	MONO	PL	RWI	SPC	TIDLOR	TWPC
AIE	BGC	DCC	GJS	KCE	MOONG	PLANB	S & J	SPI	TIPCO	U
AIRA	BGRIM	DELTA	GPI	KGI	MSC	PLANET	SAAM	SPRC	TISCO	UBE
AKP	BJCHI	DEMCO	GPSC	KKP	MST	PLAT	SABINA	SRICHA	TKS	UBIS
ALPHAX	BKI	DIMET	GSTEEL	KSL	MTC	PM	SAPPE	SSF	TKT	UEC
AMA	BLA	DRT	GUNKUL	KTB	MTI	PPP	SAT	SSP	TMD	UKEM
AMANAHA	BPP	DTAC	HANA	KTC	NBC	PPPM	SC	SSSC	TMILL	UOBKH
AMATA	BROOK	DUSIT	HARN	KWC	NEP	PPS	SCB	SST	TMT	UPF
AMATAV	BRR	EA	HEMP	KWI	NINE	PR9	SCC	STA	TNITY	UV
AP	BSBM	EASTW	HENG	L&E	NKI	PREB	SCCC	STOWER	TNL	VGI
APCS	BTS	ECL	HMPRO	LANNA	NMG	PRG	SCG	SUSCO	TNP	VIH
AQUA	BWG	EGCO	HTC	LH	NNCL	PRINC	SCN	SVI	TNR	WACOAL
ARROW	CEN	EP	ICC	LHFG	NOBLE	PRM	SEAOIL	SYMC	TOG	WHA
AS	CENTEL	EPG	ICHI	LHK	NOK	PROS	SE-ED	SYNTEC	TOP	WHAUP
ASIAN	CFRESH	ERW	IFEC	LPN	NSI	PSH	SELIC	TAE	TOPP	WICE
ASK	CGH	ESTAR	IFS	LRH	NWR	PSL	SENA	TAKUNI	TPA	WIJK
ASP	CHEWA	ETE	ILINK	M	OCC	PSTC	SGP	TASCO	TPP	XO
AWC	CHOTI	FE	INET	MAKRO	OGC	PT	SINGER	TBSP	TRU	ZEN
AYUD	CHOW	FNS	INSURE	MALEE	ORI	PTG	SIRI	TCAP	TRUE	
B	CIG	FPI	INTUCH	MATCH	PAP	PTT	SITHAI	TCMC	TSC	
BAFS	CIMBT	FPT	IRC	MBAX	PATO	PTTEP	SKR	TFG	TSTE	
BAM	CM	FSMART	IRPC	MBK	PB	PTTGC	SMIT	TFI	TSTH	
BANPU	CMC	FSS	ITEL	MC	PCSGH	PYLON	SMK	TFMAMA	TTA	
BAY	COM7	FTE	IVL	MCOT	PDG	Q-CON	SMPC	TGH	TTB	
BBL	COTTO	GBX	JKN	META	PDJ	QH	SNC	THANI	TTCL	
DECLARED										
AJ	CHG	DDD	ETC	JR	MAJOR	NUSA	RS	SSS	TQM	YUASA
ALT	CPL	DHOUSE	FLOYD	JTS	NCAP	NYT	SAK	STECH	TSI	ZIGA
APCO	CPR	DOHOME	GULF	KEX	NCL	OR	SCGP	STGT	VARO	
B52	CPW	ECF	III	KUMWEL	NOVA	PIMO	SCM	TKN	VCOM	
BEC	CRC	EKH	INOX	LDC	NRF	PLE	SIS	TMI	VIBHA	

Level	
Certified	This level indicates practical participation with thoroughly examination in relation to the recommended procedures from the audit committee or the SEC's certified auditor, being a certified member of Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) or already passed examination to ensure independence from external parties.
Declared	This level indicates determination to participate in the Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC)

Disclaimer:

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, FSS International Investment Advisory Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment results.

Note: Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of 26 October 2021) are categorised into: 1) companies that have declared their intention to join CAC, and; 2) companies certified by CAC.

Sources: The Securities and Exchange Commission, Thailand; * FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Suwat Sinsadok, CFA, FRM, ERP FSS International Investment Advisory Securities Co., Ltd


The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSS makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSS has no intention to solicit investors to buy or sell any security in this report. In addition, FSS does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price

Gunkul Engineering (GUNKUL TB)




Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
27-Feb-2020	BUY	3.80	05-Jan-2021	BUY	2.90	02-Aug-2021	BUY	5.40
22-Sep-2020	BUY	3.20	06-May-2021	BUY	5.10	28-Jan-2022	BUY	8.10

Suwat Sinsadok, CFA, FRM, ERP started covering this stock from 14-May-2020

Price and TP are in local currency

Source: FSSIA estimates

Charoen Pokphand Foods (CPF TB)



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
08-Jan-2020	BUY	36.00	25-Mar-2021	BUY	42.00	08-Oct-2021	HOLD	28.00
13-Jan-2021	BUY	37.00	12-Jul-2021	BUY	34.00			

Suwat Sinsadok, CFA, FRM, ERP started covering this stock from 29-Apr-2022

Price and TP are in local currency

Source: FSSIA estimates

Srinanaporn Marketing (SNNP TB)



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
30-Jul-2021	BUY	15.00	20-Jan-2022	BUY	20.00	-	-	-

Suwat Sinsadok, CFA, FRM, ERP started covering this stock from 29-Apr-2022

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Gunkul Engineering	GUNKUL TB	THB 5.50	BUY	The downside risks to our SoTP-based TP on GUNKUL include 1) lower-than-expected demand for electricity in Thailand, 2) declining EPC backlogs, and 3) lower-than-expected utilisation rates for solar and wind farms
Charoen Pokphand Foods	CPF TB	THB 26.50	HOLD	The key downside risks to our SoTP-based target price are the volatile pork prices in both Thailand and Vietnam which could hurt revenues and the company's gross margin. Key upside risk is faster-than-expected recovery of livestock price in region and lower feed stock cost.
Srinanaporn Marketing	SNNP TB	THB 15.30	BUY	The key downside risks to our DCF-based TP are 1) slower-than-expected demand growth and market penetration overseas, especially in Cambodia and Vietnam; 2) a lower-than-expected profit margin due to high raw material and transportation costs; and 3) higher-than-expected SG&A expenses from overseas operations.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finasia Syrus Securities Public Company Limited

FSSIA may incorporate the recommendations and target prices of companies currently covered by FSS Research into equity research reports, denoted by an 'FSS' before the recommendation. FSS Research is part of Finasia Syrus Securities Public Company Limited, which is the parent company of FSSIA.

All share prices are as at market close on 15-Jun-2022 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.